Aridis Pharmaceuticals (NASDAQ:ARDS) Upgraded to “Hold” by Zacks Investment Research

Aridis Pharmaceuticals (NASDAQ:ARDS – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Friday, Zacks.com reports.

According to Zacks, “Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company’s product pipeline consists of AR-301, AR-105, AR-101, AR-401, AR-201 and AR-501 which are in clinical stages. Aridis Pharmaceuticals, Inc. is based in San Jose, United States. “

Shares of NASDAQ:ARDS traded up $0.08 during midday trading on Friday, reaching $1.10. The company’s stock had a trading volume of 270 shares, compared to its average volume of 58,263. The firm has a market capitalization of $19.47 million, a PE ratio of -0.29 and a beta of 0.42. Aridis Pharmaceuticals has a twelve month low of $0.88 and a twelve month high of $7.72. The stock has a fifty day moving average of $1.40 and a 200 day moving average of $1.93.

Aridis Pharmaceuticals (NASDAQ:ARDS – Get Rating) last posted its quarterly earnings data on Monday, May 16th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.07. Equities analysts predict that Aridis Pharmaceuticals will post -1.79 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in ARDS. BlackRock Inc. increased its position in shares of Aridis Pharmaceuticals by 33.6% during the third quarter. BlackRock Inc. now owns 42,227 shares of the company’s stock valued at $156,000 after acquiring an additional 10,614 shares during the last quarter. Geode Capital Management LLC purchased a new stake in shares of Aridis Pharmaceuticals during the 3rd quarter worth approximately $132,000. Millennium Management LLC purchased a new stake in shares of Aridis Pharmaceuticals during the 3rd quarter worth approximately $274,000. Commonwealth Equity Services LLC purchased a new stake in shares of Aridis Pharmaceuticals during the 4th quarter worth approximately $47,000. Finally, Citadel Advisors LLC acquired a new position in shares of Aridis Pharmaceuticals in the 4th quarter valued at $34,000. Institutional investors and hedge funds own 7.46% of the company’s stock.

Aridis Pharmaceuticals Company Profile (Get Rating)

Aridis Pharmaceuticals, Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

See Also